What Ionis Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 2 | 2 |
| Sells | 2 | 123 |
| Total trades | 10 | 242 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 23,274 | 1,676,905 |
| Disposed | 1,410 | 1,651,425 |
| Net activity | +21,864 | +25,480 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Swayze Eric | EVP Research | Oct 16 | Sale for tax withholding · S | −53 | $43.54 | −$2.31K | 390 |
| Devers Shannon L. | EVP, Chief Human Resources Ofc | Oct 16 | Sale for tax withholding · S | −1,357 | $43.54 | −$59.1K | 17,811 |
| Swayze Eric | EVP Research | Oct 15 | Exercise / conversion · M | +125 | — | — | 443 |
| Devers Shannon L. | EVP, Chief Human Resources Ofc | Oct 15 | Exercise / conversion · M | +2,820 | — | — | 19,168 |
| Birchler Brian | EVP, Corp and Development Ops | Aug 31 | Other Transaction · J | +58 | $51.31 | +$2.98K | 102,883 |
| O'neil Patrick R. | EVP CLO & General Counsel | Aug 31 | Other Transaction · J | +63 | $51.31 | +$3.23K | 59,205 |
| Monia Brett P | Chief Executive Officer | Aug 31 | Other Transaction · J | +98 | $51.31 | +$5.03K | 242,760 |
| Bennett C Frank | EVP, Chief Scientific Officer | Aug 31 | Other Transaction · J | +110 | $51.31 | +$5.64K | 60,128 |
| Hayden Michael R | Director | Jul 31 | Open-market buy · P | +5,000 | $51.60 | +$258K | 24,000 |
| Hayden Michael R | Director | Jul 30 | Open-market buy · P | +15,000 | $53.38 | +$801K | 19,000 |
| Berthelsen Spencer R | Director | Jul 15 | Exercise / conversion · M | +5,220 | — | — | 161,233 |
| Herman Joan E | Director | Jul 15 | Exercise / conversion · M | +5,220 | — | — | 51,306 |
| Diaz Allene M. | Director | Jul 07 | Disclosed 10b5-1 sale · S | −10,111 | $85.42 | −$864K | 3,811 |
| Diaz Allene M. | Director | Jul 07 | Exercise / conversion · M | +10,111 | $47.11 | +$476K | 13,922 |
| Bennett C Frank | EVP, Chief Scientific Officer | Jul 07 | Disclosed 10b5-1 sale · S | −15,000 | $85.46 | −$1.28M | 0 |
| Bennett C Frank | EVP, Chief Scientific Officer | Jul 07 | Other Transaction · J | +15,000 | — | — | 15,000 |
| Bennett C Frank | EVP, Chief Scientific Officer | Jul 07 | Disclosed 10b5-1 sale · S | −5,536 | $83.58 | −$463K | 75,018 |
| Kordasiewicz Holly B. | EVP, Chief Development Officer | Jul 07 | Disclosed 10b5-1 sale · S | −362 | $84.30 | −$30.5K | 22,096 |
| Klein Joseph Iii | Director | Jul 01 | Disclosed 10b5-1 sale · S | −11,419 | $79.04 | −$903K | 11,014 |
| Klein Joseph Iii | Director | Jul 01 | Disclosed 10b5-1 sale · S | −99 | $79.45 | −$7.87K | 22,433 |
Loading...
